NASDAQ:EPRX
Eupraxia Pharmaceuticals Inc.
Eupraxia Pharmaceuticals Inc.'s revenue was $0 in fiscal 2025. The diluted share count rose 17.8%.Summary generated from Eupraxia Pharmaceuticals Inc.'s SEC filings. Latest annual report filed Mar 13, 2026.
Key statistics
Fiscal 2025 from SEC filings. MethodologyRevenue (FY25)$0
Revenue growthn/a
Revenue, 5-yr CAGRn/a
Gross marginn/a
Operating marginn/a
Net marginn/a
ROICn/a
Return on equity−66.8%
Debt / equityn/a
Free cash flown/a
FCF marginn/a
Share count change+17.8%
Financials
| Item | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue | n/a | 0 | 0 | 0 |
| Operating income | n/a | n/a | n/a | n/a |
| Net income | −18 | −28 | −26 | −39 |
| Free cash flow | n/a | n/a | n/a | n/a |
Recent filings
- 6-KCurrent report (foreign issuer)
Oct 9, 2026 - 6-KCurrent report (foreign issuer)
Sep 30, 2026 - 6-KCurrent report (foreign issuer)
Sep 8, 2026 - 6-KCurrent report (foreign issuer)
Aug 13, 2026 - 6-KCurrent report (foreign issuer)
Aug 11, 2026 - 6-KCurrent report (foreign issuer)
Jul 15, 2026 - 6-KCurrent report (foreign issuer)
Jul 13, 2026 - 6-KCurrent report (foreign issuer)
Jul 7, 2026